Novartis (NYSE:NVS) is reportedly planning to close MorphoSys’s sites in Boston and Munich, Germany, a move that is expected to impact around 300 workers. The sites are slated to be closed by ...

The sites in Munich and Boston will be shut down by the end of ... in spleen volume after 24 weeks' treatment. However, MorphoSys' drug was unable to achieve the key secondary objective of ...

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to HIBio. The German ...

“While Royalty Pharma does not generally sell royalty investments, Novartis’ acquisition of MorphoSys created a unique opportunity to convert a fixed stream of long-term payments with no ...

Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan ...

"While Royalty Pharma does not generally sell royalty investments, Novartis' acquisition of MorphoSys created a unique opportunity to convert a fixed stream of long-term payments with no potential ...